Notwithstanding the advancement of several small molecule inhibitors aimed at the PI3K/AKT/mTOR pathway [18, 19], the upstream regulators and molecular mechanisms driving the aberrant PI3K/AKT/mTOR pathway in AML remain incompletely understood. This evidence concerns the gene AKT1 and acute myeloid leukemia.